Develops small-molecule drug candidates for patients with cancer and genetic diseases, using computational and experimental methods to target genetically defined conditions.
10-K for FY2025, filed Feb 26, 2026
Elevar pays Relay for global rights to develop and commercialize lirafugratinib, with payments at signing and when materials are transferred, plus milestones and royalties based on sales.
10-K for FY2025, filed Feb 26, 2026
$15.4M
10-K for FY2025, filed Feb 26, 2026
$15.4M ↗
Elevar received global development and commercialization rights to lirafugratinib through an exclusive license; Relay retains those rights for its other active programs.
10-K for FY2025, filed Feb 26, 2026
No. It lost $276.5M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$81.7MView ↗
Growing. Revenue grew 5.1x in 4 years, from $3M in FY2021 to $15.4M in FY2025, about 50% a year.
Licensing and ending programs
The earlier report included a fibroblast growth factor receptor drug and a Genentech collaboration; the latest report says the former was licensed to Elevar and Genentech's agreement ended, with Relay stopping work on the latter.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026We are advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including our lead product…View ↗
RLY-4008. In the third quarter of 2020, we initiated a first-in-human clinical trial for RLY-4008, or the RLY-4008 ReFocus Trial, a potent…View ↗
GDC-1971 (formerly known as RLY-1971). In the first quarter of 2020, we initiated a Phase 1a clinical trial for RLY-1971, our inhibitor of…View ↗
Competes with Novartis, AstraZeneca, Roche Holding, Celcuity, Totus Medicines, Eli Lilly and, OnKure, Kaken Pharmaceutical, Palvella Therapeutics, Pfizer, Revolution Medicines, Amicus Therapeutics, Sanofi, Takeda, and Protalix Biotherapeutics
10-K for FY2025, filed Feb 26, 2026We expect that zovegalisib will compete against approved medicines, Piqray (alpelisib), a non-selective PI3Kα inhibitor marketed by…View ↗
Loading...